title: [Outcome of the cases of chronic liver disease type C who exhibited long term response to interferon therapy; comparison of the cases with or without serum HCV-RNA].
abstract: We evaluated the outcome of 71 Japanese patients with chronic hepatitis C who exhibited a sustained normal level of serum ALT for one to five years after the cessation of interferon (IFN) therapy. Patients were classified into two groups: 9 (13%) cases with a sustained positive for serum HCV-RNA (incomplete responders: ICR) and 62 (87%) cases with a sustained negative for serum HCV-RNA (complete responders: CR). The anti-C100-3 titer was similarly decreased in both groups especially up to one year after cessation of IFN becoming negative in 50% of each group over a 4-year period. The anti-C-22 titer was also decreased in the CR group and stabilized at about 100U (RIA). The titer of anti-C-22 was either increased or maintained at pretreatment levels in most cases of ICR. Monitoring of anti-C-22 may be useful in distinguishing the presence of HCV viremia from a previous HCV infection. According to the backgrounds between both groups, ICR cases were significantly older and more often of genotype 1b (67%) than CR cases (1b; 32%), however there were no significant differences in sex, liver histology or pretreatment levels of HCV-RNA. Serum levels of HCV-RNA in ICR cases after IFN therapy either increase or remained similar to pretreatment levels however most patients with ICR showed an improvement in liver histology. Thus if the serum ALT level remained normal in case of ICR the objective of administering IFN to treat chronic hepatitis C was considered to have been achieved despite the persistence of HCV viremia.
authors.affiliation: Second Department of Internal Medicine, St. Marianna University School of Medicine.
authors.forename: H
authors.initials: H
authors.lastname: Tohyama
authors.forename: S
authors.initials: S
authors.lastname: Iwabuchi
authors.forename: M
authors.initials: M
authors.lastname: Takatori
mesh_terms: D005260:Female; D016174:Hepacivirus / Q000235:genetics / Q000302:isolation & purification*; D006526:Hepatitis C / Q000628:therapy* / Q000821:virology; D006801:Humans; D007372:Interferons / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D012367:RNA, Viral / Q000097:blood*; D016896:Treatment Outcome; D014766:Viremia / Q000628:therapy
chemical_list: D012367:RNA, Viral; D007372:Interferons